Living with Type 2 Diabetes can be challenging, especially when it comes to finding the right treatment. Dr. Frank's team is here to help you navigate this journey and find the personalised treatment you need.
Missed Ozempic due to shortage in the last 12-18 months? Started on alternatives like Gliclazide or Insulin? We understand your frustration
Have you been unable to achieve your diabetes target (HbA1c) despite trying Ozempic or other GLP1 agonist therapies like Rybelsus, Victoza, Bydureon, or Trulicity?
Are you currently on GLP1 agonist therapies (Ozempic, Rybelsus, Victoza, Bydureon, Trulicity) but facing challenges in consistently accessing your treatment?
Discover the science behind GIP & GLP-1, our innovative medication designed to target three fundamental mechanisms for optimal weight management.
Will guide + support you through your weight loss journey with monthly review clinics + unlimited well being calls.*
*costs may be incurred depending on your chosen service/subscription type
Accelerate your results + make informed decisions. Developed by Dr Franklin Joseph and our specialist dietitian.
If you're unable to qualify for NHS treatment with Ozempic (Semaglutide) or Mounjaro (Tirzepatide), Dr. Frank can provide the help you need.
Your diabetes is well-controlled, which means you don't meet the criteria for treatment eligibility.
Your BMI and weight do not meet the necessary criteria for eligibility.
You're not currently taking three tablets for blood sugar control.
Mounjaro
£225.00
£160.00/month
Wegovy
This product is currently out of stock. Click below for restock notifications.
“I’m at my honeymoon weight which was in April 1978. I couldn’t be happier.”
“I’ve never felt so comfortable in my own skin.”
“The sole solution that has been effective after my long struggle”
Make an informed decision based on the data collected.
The study found that Mounjaro doses of 5 mg, 10 mg, and 15 mg helped people lose more weight than semaglutide 1 mg by the 40th week. Specifically, the 15 mg Mounjaro dose led to twice as much weight loss as the semaglutide dose by that time.*
Get Started1https://www.nejm.org/doi/full/10.1056/nejmoa2107519
Based on a 68-week clinical study of once-weekly injection of a GLP-1 receptor agonist compared to a placebo with 1961 participants.
Get Started¹ https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
All 3 doses of once weekly mounjaro led to clinically meaningful and sustained weight reduction in obese adults
Get Started¹ https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?
